ArticleThe oncologist2026
Cognitive changes associated with chemotherapy in breast cancer: an assessment of social cognition and executive functions in Peruvian patients.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCognitive impairment related to chemotherapy-commonly referred to as "chemo brain"-is a well-documented phenomenon among breast cancer patients. These impairments affect memory, attention, executive function, and social cognition, yet remain understudied in low- and middle-income countries. In Peru, where populations present a high proportion of Amerindian ancestry and distinct sociocultural factors, evidence is scarce.
methodsWe conducted a longitudinal study of 143 Peruvian women aged 28-64 years, newly diagnosed with early-stage breast cancer and naïve to chemotherapy, treated at the National Institute of Neoplastic Diseases (INEN) in Lima. Cognitive function was assessed using the Addenbrooke's Cognitive Examination (ACE), the INECO Frontal Screening Test (IFS), and a Facial Emotion Recognition (FER) task to evaluate social cognition. Baseline tests were performed before the start of treatment for each patient, and post-treatment tests were performed every 3 months. Global genetic ancestry was estimated using the ADMIXTURE algorithm based on the Affymetrix Precision Medicine Research Array.
resultsNative American ancestry accounted for 77.8% of the study population. Post-chemotherapy assessments revealed cognitive impairment in 21% of patients based on FER, 15% on ACE, and 12% on IFS. Higher educational attainment was associated with better cognitive performance across all domains.
conclusionChemotherapy was associated with measurable cognitive decline in a subset of Peruvian breast cancer patients. Brief and culturally adaptable tools such as the FER test offer a promising approach for routine cognitive screening in oncology settings, particularly in resource-limited contexts. Incorporating these assessments into standard care may facilitate early detection and more personalized supportive interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.